An independent editorial publisher — not a clinic

What this site is

Retatrutide Medicine is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). The site is organized around the clinical trial record — Phase 1b, Phase 2 obesity and type 2 diabetes trials, MASLD substudy, structural biology, and systematic reviews — with every quantitative claim cited to a primary or review source.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain modifier "medicine" is editorial framing — it situates this project within the literature on a drug being studied in medicine, not within a medical practice. This is an important distinction: nothing on this site constitutes clinical guidance, a prescriber recommendation, or a treatment plan.

What this site is not

Not a clinic or telehealth service. We do not offer consultations, treat patients, or employ healthcare staff. Nothing here is a substitute for a conversation with a licensed clinician.

Not a vendor or pharmacy. We do not sell, link to vendors of, or facilitate the procurement of retatrutide or any other compound. Retatrutide is not an approved drug; this site does not provide sourcing information.

Not medical advice. The content here describes what published studies have measured. It is not a recommendation to take any compound, adjust any medication, or pursue any course of treatment.

Not affiliated with Eli Lilly. This site is an independent editorial project and has no relationship with the developer of retatrutide.

Editorial standards

Every quantitative claim on this site cites a primary study or peer-reviewed review. No findings are invented; no citations are fabricated. The accuracy guard for this site requires that retatrutide is characterized throughout as investigational, not approved — distinguishing it clearly from approved GLP-1-class compounds. Brand names of approved drugs are not used on this site; generic (INN/USAN) names only.

Real-world community reports (on the effects page) are clearly labeled as anecdotal accounts, separated from trial findings, and attributed to community sources without reproducing those URLs as outbound links. The anecdotal label is verbatim in the section text.

This site's content is updated as peer-reviewed data are published. Phase 3 TRIUMPH results, when published and peer-reviewed, will be added to the trial record with appropriate citation.